Acta Cardiologica Sinica最新文献

{"title":"Long-Term Survival of Patients with Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Single-Center Cohort.","authors":"Yu Jui Hsieh,&nbsp;Wan-Jing Ho,&nbsp;Chia-Pin Lin,&nbsp;Shue-Fen Luo,&nbsp;Kuang-Hui Yu,&nbsp;Ji-Yih Chen,&nbsp;Fu-Chih Hsiao,&nbsp;Chieh-Yu Chang","doi":"10.6515/ACS.202305_39(3).20221104A","DOIUrl":"https://doi.org/10.6515/ACS.202305_39(3).20221104A","url":null,"abstract":"<p><p>Pulmonary arterial hypertension (PAH) is a rare but severe complication of connective tissue disease (CTD). CTD-associated PAH (CTD-PAH) is the most common subgroup of PAH in East Asia. We prospectively collected 41 patients with CTD-PAH and followed them for a mean period of 43 ± 36 months. The long-term survival rates of the CTD-PAH patients at 1, 2, 3 and 5 years were 90%, 80%, 77%, and 60%, respectively. The non-survivors had more dilated main pulmonary arteries, higher pulmonary artery pressure and pulmonary vascular resistance (PVR). PAH-specific therapy resulted in improvements in functional class, 6-minute walk distance, serum uric acid, right ventricular function and PVR. Increased C-reactive protein during follow-up, indicating inflammatory processes, was also crucial for the management of CTD-PAH. Therefore targeting both PAH and inflammation is important in this specific subgroup of PAH. The results of this study may help develop treatment strategies for CTD-PAH patients.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 3","pages":"469-479"},"PeriodicalIF":1.9,"publicationDate":"2023-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10203717/pdf/acs-39-469.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9518819","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repetition of Paclitaxel-Coated Devices for the Treatment of Lower Extremity Artery Disease: Mortality Outcomes and Predictors.","authors":"Shih-Jung Jang,&nbsp;Chien-An Hsieh,&nbsp;Yao-Ting Chang,&nbsp;I-Chih Chen,&nbsp;Kuan-Liang Liu,&nbsp;I-Shiang Tzeng,&nbsp;Hsin-Hua Chou,&nbsp;Yu-Lin Ko,&nbsp;Heng-Chia Chang,&nbsp;Hsuan-Li Huang","doi":"10.6515/ACS.202303_39(2).20220815B","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220815B","url":null,"abstract":"<p><strong>Background: </strong>A recent meta-analysis reported late excess mortality in patients treated with paclitaxel-coated devices (PCDs) for symptomatic femoropopliteal disease. However, this finding is controversial.</p><p><strong>Objectives: </strong>To investigate the impact on mortality and predictors of repeat exposure to PCDs in patients with lower extremity peripheral arterial disease (LE-PAD).</p><p><strong>Methods: </strong>We analyzed registry patient-level data from two centers. A total of 214 patients were enrolled, and stratified based on terciles of cumulative dose of paclitaxel. We treated 134 patients with a single PCD exposure and 80 with multiple PCD exposures. We used the follow-up index (FUI) in Kaplan-Meier survival estimates to minimize potential selection bias. We used Cox proportional hazard and splines models to determine the predictors of mortality and assess their relationships with mortality.</p><p><strong>Results: </strong>The mean cumulative dose of paclitaxel was significantly different among groups (6.40 mg vs. 15.06 mg vs. 38.57 mg, p < 0.001). The 5-year FUI (0.93 ± 0.19 vs. 0.94 ± 0.18 vs. 0.95 ± 0.15, p = 0.836) and survival rates were not different (65.4% vs. 51.9% vs. 72.0%, p = 0.148). There was no dose-response association between paclitaxel dosage and death (p = 0.297). The predictors of death were congestive heart failure, stroke, dialysis dependence, neutrophil-lymphocyte ratio (NLR) > 3, age > 71 years, and body mass index (BMI) < 20 kg/m². Spline model analysis validated the non-linear associations between mortality, age, BMI, and NLR.</p><p><strong>Conclusions: </strong>Repeated PCD exposure for LE-PAD did not result in excess late mortality. Predictors of mortality might change over time, and continuous variables had non-linear relationships with death.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"331-342"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999189/pdf/acs-39-331.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Effects of Post-Acute Care in Patients with Heart Failure in Taiwan: A Single Center Experience.","authors":"Pei-Yi Wang, Wen-Chih Lin, Pei-Chun Hsieh, Sheng-Hsiang Lin, Ping-Yen Liu, Ting-Hsing Chao, Chih-Hsin Hsu","doi":"10.6515/ACS.202303_39(2).20220923B","DOIUrl":"10.6515/ACS.202303_39(2).20220923B","url":null,"abstract":"<p><strong>Background: </strong>The National Health Insurance Administration in Taiwan has promoted the heart failure post-acute care (HF-PAC) program as a means to provide proactive integrated care within the optimal treatment timeframe to enhance functional recovery after acute decompensated heart failure (HF).</p><p><strong>Objectives: </strong>The aim of this program was to reduce HF readmission rates, improved medication prescription rates, and improve the quality of life in HF patients.</p><p><strong>Methods: </strong>Patients who had a reduced left ventricular ejection fraction (LVEF) of ≤ 40% were included and followed up for 6 months after discharge. They underwent cardiac rehabilitation and physiological, and nutritional status evaluations. The main clinical outcomes of the HF-PAC program were guideline-directed medical therapy prescription rate and 6-month readmission rate.</p><p><strong>Results: </strong>A total of 122 patients were recruited from June 2018 to December 2020 at a medical center in southern Taiwan. The patients' activities of daily living, nutritional status, quality of life and LVEF were significantly improved during the HF-PAC program. More than 95% of the patients received guideline-directed medical prescriptions at the end of the HF-PAC program. The cardiovascular-related 6-month re-admission rate after the HF-PAC program ended was 27.7%, and it could be predicted by the New York Health Association functional class [hazard ratio (HR) 95% confidence interval (95% CI) = 4.12 (1.36-12.46)], value of the Mini Nutritional Assessment - Short Form [HR (95% CI) = 0.46 (0.31-0.68)] and LVEF [HR (95% CI) = 0.95 (0.91-0.99)].</p><p><strong>Conclusions: </strong>By incorporating multidisciplinary healthcare teams, the HF-PAC program improves the guideline- directed medical therapy prescription rate, thus improving patients' cardiac function, physical activity recovery, the quality of life, and also reduces their readmission rate.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"287-296"},"PeriodicalIF":1.8,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999181/pdf/acs-39-287.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Roles of Aerobic Exercise and Folate Supplementation in Hyperhomocysteinemia-Accelerated Atherosclerosis.","authors":"Xingming Zhong,&nbsp;Rong He,&nbsp;Shaohua You,&nbsp;Bo Liu,&nbsp;Xiujie Wang,&nbsp;Jieming Mao","doi":"10.6515/ACS.202303_39(2).20221027A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20221027A","url":null,"abstract":"<p><strong>Background: </strong>Hyperhomocysteinemia (HHcy) is an independent risk factor for atherosclerosis. Effective interventions to reduce HHcy-accelerated atherosclerosis are required.</p><p><strong>Objectives: </strong>This study aimed to investigate the effects of aerobic exercise (AE) and folate (FA) supplementation on plasma homocysteine (Hcy) level and atherosclerosis development in a mouse model.</p><p><strong>Methods: </strong>Six-week-old female apoE-/- mice were grouped into five groups (N = 6-8): HHcy (1.8 g/L DL-homocysteine (DL-Hcy) in drinking water), HHcy + AE (1.8 g/L DL-Hcy and aerobic exercise training on a treadmill), HHcy + FA (1.8 g/L DL-Hcy and 0.006% folate in diet), HHcy + AE + FA (1.8 g/L DL-Hcy, 0.006% folate, and aerobic exercise training on a treadmill), and a control group (regular water and diet). All treatment was sustained for 8 weeks. Triglyceride, cholesterol, lipoprotein, and Hcy levels were determined enzymatically. Plaque and monocyte chemoattractant protein-1 (MCP-1) expression levels in mouse aortic roots were evaluated by immunohistochemistry.</p><p><strong>Results: </strong>Compared to the HHcy group (18.88 ± 6.13 μmol/L), plasma Hcy concentration was significantly reduced in the HHcy + AE (14.79 ± 3.05 μmol/L, <i>p</i> = 0.04), HHcy + FA (9.4 ± 3.85 μmol/L, <i>p</i> < 0.001), and HHcy + AE + FA (9.33 ± 2.21 μmol/L, <i>p</i> < 0.001) groups. Significantly decreased aortic root plaque area and plaque burden were found in the HHcy + AE and HHcy + AE + FA groups compared to those in the HHcy group (both <i>p</i> < 0.05). Plasma MCP-1 level and MCP-1 expression in atherosclerotic lesions were significantly decreased in the HHcy + AE and HHcy + AE + FA groups compared to the HHcy group (all <i>p</i> < 0.05).</p><p><strong>Conclusions: </strong>AE reduced atherosclerosis development in HHcy apoE-/- mice independently of reducing Hcy levels. FA supplementation decreased plasma Hcy levels without attenuating HHcy-accelerated atherosclerosis. AE and FA supplementation have distinct mechanisms in benefiting atherosclerosis.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"309-318"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999187/pdf/acs-39-309.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of Optical Coherence Tomography-Guided Primary Percutaneous Coronary Intervention in Patients with Acute Coronary Syndrome.","authors":"Hiroshi Okamoto,&nbsp;Teruyoshi Kume,&nbsp;Takeshi Nishi,&nbsp;Satoshi Koto,&nbsp;Yoshitaka Sasahira,&nbsp;Ryotaro Yamada,&nbsp;Terumasa Koyama,&nbsp;Tomoko Tamada,&nbsp;Koichiro Imai,&nbsp;Yoji Neishi,&nbsp;Shiro Uemura","doi":"10.6515/ACS.202303_39(2).20220729A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220729A","url":null,"abstract":"<p><strong>Background: </strong>Optical coherence tomography (OCT) is currently used as a guide for percutaneous coronary intervention (PCI), however its clinical benefit in comparison with intravascular ultrasound (IVUS) remains unclear in patients with acute coronary syndrome (ACS).</p><p><strong>Objectives: </strong>The purpose of this study was to evaluate the clinical efficacy of OCT-guided PCI in comparison with IVUS-guided PCI in patients with ACS.</p><p><strong>Methods: </strong>The study participants comprised 280 consecutive ACS patients who underwent primary PCI for de novo culprit lesions under OCT or IVUS guidance.</p><p><strong>Results: </strong>Compared with the IVUS-guided group, the OCT-guided group had lower Killip classification (p < 0.001) and lower creatinine level at baseline (0.80 ± 0.37 mg/dl vs. 1.13 ± 1.29 mg/dl, p = 0.004). Fluoroscopy time and total procedure time were significantly shorter in the OCT-guided group than in the IVUS-guided group (32 ± 13 min vs. 41 ± 19 min, p < 0.001, and 98 ± 39 min vs. 127 ± 47 min, p = 0.002, respectively). The major adverse cardiovascular event-free survival curves were similar between the OCT- and IVUS-guided groups after adjusting for clinical background using propensity score (log-rank p = 0.328).</p><p><strong>Conclusions: </strong>After adjusting for clinical background, OCT-guided PCI could provide comparable clinical outcomes to IVUS-guided PCI in patients with ACS. Shorter fluoroscopy time and total procedure time with OCT may reduce patient radiation exposure and also improve hospital workflow.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"266-276"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999186/pdf/acs-39-266.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455849","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Management of Restenosis after Stenting in Left Main Coronary Artery Disease.","authors":"Chen-Wei Huang,&nbsp;Mu-Shiang Huang,&nbsp;Pei-Fang Su,&nbsp;Ting-Hsing Chao,&nbsp;Cheng-Han Lee,&nbsp;Ping-Yen Liu","doi":"10.6515/ACS.202303_39(2).20220821A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220821A","url":null,"abstract":"<p><strong>Background: </strong>The optimal alternative treatment strategy to coronary artery bypass graft surgery (CABG) for in-stent restenosis (ISR) in left main (LM) coronary artery disease remains uncertain.</p><p><strong>Methods: </strong>We retrospectively screened all intervention reports from an intervention database and extracted those mentioning an LM stent. We then manually confirmed reports involving LM ISR and divided them into two groups, those in which the patient received a new drug-eluting stent (new-DES) strategy, and those in which the patient received a drug-coated balloon (DCB) only. A composite endpoint of major adverse cardiovascular events (MACEs) and each individual endpoint were compared. We also performed a brief analysis of similar designed studies.</p><p><strong>Results: </strong>Between the new-DES (n = 40) and DCB-only (n = 22) groups, during median respective follow-up times of 581.5 and 642.5 days, no significant statistical differences were detected in MACEs (50.0% vs. 50.0%, p = 0.974), cardiovascular death (27.5% vs. 13.6%, p = 0.214), nonfatal myocardial infarction (30.0% vs. 31.8%, p = 0.835), or target lesion revascularization (35.0% vs. 45.5%, p = 0.542). We analyzed four similar studies and found comparable MACE findings (odds ratio: 0.85, 95% CI: 0.44-1.67).</p><p><strong>Conclusions: </strong>Our findings support both DCB angioplasty and repeat DES implantation for LMISR lesions in patients who were clinically judged to be unsuitable for CABG; the treatments achieved comparable clinical results in terms of MACEs in the medium term.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"277-286"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999179/pdf/acs-39-277.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101435","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Combined Left Ventricular Ejection Fraction and N-Terminal pro-B-type Natriuretic Peptide after Sacubitril/Valsartan for Predicting Outcomes in Patients with Heart Failure with Reduced Ejection Fraction.","authors":"Ching-Chang Fang,&nbsp;Yeun Tarl Fresner Ng Jao","doi":"10.6515/ACS.202303_39(2).20220926A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220926A","url":null,"abstract":"<p><strong>Background: </strong>The aim of this study was to determine whether a combined increase of ≥ 10% in left ventricular ejection fraction (LVEF) and decrease in N-terminal pro-B-type natriuretic peptide (NT pro-BNP) to < 1000 pg/mL after treatment with sacubitril/valsartan (SAC/VAL) in patients with heart failure with reduced ejection fraction (HFrEF) translated to better treatment outcomes in a real-world Taiwanese population.</p><p><strong>Methods: </strong>This is a single-center, prospective, non-randomized, observational study. Consecutive patients with HFrEF were treated with SAC/VAL and followed up for at least 12 months. The primary endpoint was a change in LVEF and reduction in NT pro-BNP at 12 months. The secondary outcomes were death and heart failure (HF) rehospitalization.</p><p><strong>Results: </strong>A total of 105 patients were analyzed after 12 months of SAC/VAL treatment. The mean age was 66.0 ± 11.6 years, and the mean LVEF and NT pro-BNP were 33.6 ± 6.7% and 4462.7 ± 5851.7 pg/mL respectively. The mean LVEF significantly increased to 50.5 ± 10.3% (p < 0.001), while NT pro-BNP decreased to 1270.3 ± 2368.2 pg/mL (p = 0.001) at 12 months, with the greatest changes occurring in the first 3 months of treatment (p < 0.001). Five patients died and 12 were rehospitalized for HF. None of the patients in the responder group died compared to 5 deaths in the non-responder group (p = 0.039). Combined ≥ 10% LVEF increase and NT pro-BNP of < 1000 pg/mL was an independent predictor of death and HF rehospitalization (p = 0.019).</p><p><strong>Conclusions: </strong>SAC/VAL treatment resulted in significant improvements in LVEF, reduced NT pro-BNP level, death and HF hospitalization. Taken separately, an NT pro-BNP level of < 1000 pg/mL was a better predictor than ≥ 10% LVEF increase. Combining both variables predicted fewer deaths and HF rehospitalizations. Even with failure to reach the target dose, SAC/VAL still had significantly beneficial treatment outcomes in Taiwanese patients.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"297-308"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999178/pdf/acs-39-297.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9455850","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pulse Wave Analysis Predicts Invasive Hemodynamics in Pre-Capillary Pulmonary Hypertension.","authors":"Yen-Yu Liu,&nbsp;Shu-Hao Wu,&nbsp;Cheng-Ting Tsai,&nbsp;Fang-Ju Sun,&nbsp;Charles Jia-Yin Hou,&nbsp;Hung-I Yeh,&nbsp;Yih-Jer Wu","doi":"10.6515/ACS.202303_39(2).20220826A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220826A","url":null,"abstract":"<p><strong>Background: </strong>We tested the hypothesis that non-invasive pulse wave analysis (PWA)-derived systemic circulation variables can predict invasive hemodynamics of pulmonary circulation and the indicator of right heart function, N-terminal pro-brain natriuretic peptide (NT-proBNP), in patients with precapillary pulmonary hypertension (PH).</p><p><strong>Methods: </strong>This prospective study enrolled patients with group 1 and 4 PH who had complete PWA, NT-proBNP, and hemodynamics data. Risk assessment-based \"hemodynamic score (HS)\" and principal component analysis-based PWA variable grouping were determined/performed. Models of hierarchical multiple linear regression (HMLR) and receiver operating characteristic (ROC) curves were used to determine the relationships of PWA variables with HS and NT-proBNP and to predict the latter parameters.</p><p><strong>Results: </strong>Fifty-three PWAs were included. PWA variables were classified into 4 eigenvalue principal components (representing 90% configuration). Univariate analysis showed that left ventricular ejection time (LVET) was significantly negatively associated with HS and NT-proBNP levels. HMLR analysis showed that LVET was still significantly, negatively, and independently associated with HS (B = -0.006 [-0.010~-0.001]) and NT-proBNP (B = -13.47 [-21.20~-5.73]). ROC curve analysis showed that LVET > 306.9 msec and > 313.2 msec predicted the low-risk group of HS (AUC: 0.802; p = 0.001; sensitivity: 100%; and specificity: 59%) and low-to-intermediate risk levels of NT-proBNP (AUC: 0.831; p < 0.001; sensitivity: 100%; and specificity: 59%).</p><p><strong>Conclusions: </strong>The non-invasive PWA parameter, LVET, is an independent predictor of invasive right heart HS and NT-proBNP levels; it may serve as a novel biomarker of right ventricular function in patients with pre-capillary PH.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"319-330"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999185/pdf/acs-39-319.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9097034","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Right Ventricle Takotsubo Cardiomyopathy with Abnormal Echocardiographic Right Heart Haemodynamics.","authors":"Rodney Yu-Hang Soh,&nbsp;Lauren Kay Mance Evangelista,&nbsp;Tiong-Cheng Yeo,&nbsp;Ching-Hui Sia","doi":"10.6515/ACS.202303_39(2).20221030A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20221030A","url":null,"abstract":"","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"353-356"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999183/pdf/acs-39-353.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cancer-Associated Thrombosis: A Taiwanese Perspective on Therapeutic Options with Focus on Non-Vitamin K Antagonist Oral Anticoagulants.","authors":"Yu-Yun Shao,&nbsp;Ching-Liang Ho,&nbsp;Cheng-Shyong Chang,&nbsp;Chia-Lun Chang,&nbsp;Jen-Kuang Lee,&nbsp;Hung-Ju Lin,&nbsp;Hui-Hua Hsiao,&nbsp;Ta-Chung Chao,&nbsp;Ching-Yeh Lin,&nbsp;Chuang-Chi Liaw","doi":"10.6515/ACS.202303_39(2).20220719A","DOIUrl":"https://doi.org/10.6515/ACS.202303_39(2).20220719A","url":null,"abstract":"<p><p>Cancer-associated thrombosis (CAT) is a common complication of malignancies. Patients with CAT are at risk of venous thromboembolism recurrence, but also at risk of bleeding while anticoagulated. Taiwanese patients are perceived to have a lower incidence of CAT, likely leading to false reassurance for Taiwanese patients with cancer. Because of this, oncologists and cardiologists from multiple medical institutions in Taiwan have set forth to provide clinical consensus guidelines on the management of CAT, based on local clinical practices and guided by predominant international clinical practice guidelines. This paper aims to describe the current disease burden of cancer-associated venous thromboembolism in Taiwanese cancer patients, and discusses the unmet needs and gaps in the management of this medical complication. It also outlines diagnostic and management strategies relevant to the different treatment options available, such as non-vitamin K antagonist oral anticoagulants.</p>","PeriodicalId":6957,"journal":{"name":"Acta Cardiologica Sinica","volume":"39 2","pages":"242-253"},"PeriodicalIF":1.9,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9999188/pdf/acs-39-242.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}